Clinical Trial Update: Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial comparing a single-dose versus twice-yearly zoledronic acid in patients with early-stage breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Zoledronic acid (Zometa) (zoledronic acid)

Snippet

Sponsor: Ottawa Hospital Research Institute | Conditions: Early-stage Breast Cancer | Phase 4 | Status: COMPLETED